Jazz Pharmaceuticals plc (JAZZ) key performance indicators and operating metrics (50 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Idiopathic hypersomnia patients | 5.85K | FY2026-Q2 |
| Active Xywav patients | 17.13K | FY2026-Q2 |
| Net patient adds | 525.00 | FY2026-Q2 |
| Narcolepsy patients | 11.28K | FY2026-Q2 |
| XyRem net product sales | 30.5M | FY2026-Q2 |
| Epidiolex and Epidyolex net product sales | 292.1M | FY2026-Q2 |
| Xywav net product sales | 471.2M | FY2026-Q2 |
| Oncology net product sales | 362.3M | FY2026-Q2 |
| Zepzelca net product sales | 106M | FY2026-Q2 |
| Non-GAAP adjusted diluted earnings per share | 5.71 USD_per_share | FY2026-Q2 |
| Non-GAAP adjusted net income | 396.4M | FY2026-Q2 |
| Ziihera net product sales | 15.2M | FY2026-Q2 |
| Sleep net product sales | 501.7M | FY2026-Q2 |
| Total neuroscience revenue | 848M | FY2025-Q4 |
Back to JAZZ overview · JAZZ earnings · JAZZ holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.